HealthMore in Health→
Roche keeps the faith in giredestrant after a setback in first-line breast cancer
Key Takeaways
- Roche says it still has high sales expectations for investigational breast cancer pill giredestrant.
- CEO Thomas Schinecker said the drug could outsell Herceptin.
- The statement comes despite giredestrant’s failure in a first-line trial earlier this year.
DE
DT Editorial Team··via endpoints.news
